Evidence map›Paper›PMID 31926628›Full record

ArticleRedox biology2020

Complex interrelationships between nitro-alkene-dependent inhibition of soluble epoxide hydrolase, inflammation and tumor growth.

Hyun-Ju Cho, Christopher Harry Switzer, Alisa Kamynina, Rebecca Charles, Olena Rudyk, Tony Ng, Joseph Robert Burgoyne, Philip Eaton

Open access · goldAbstract read
In one paragraph

Article in Redox biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Enhancing cancer immunotherapy via inhibition of soluble epoxide hydrolase.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Hyun-Ju ChoWilliam Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London, EC1M6BQ, UK.
Christopher Harry SwitzerWilliam Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London, EC1M6BQ, UK.
Alisa KamyninaWilliam Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London, EC1M6BQ, UK.
Rebecca CharlesWilliam Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London, EC1M6BQ, UK.
Olena RudykKing's College London, School of Cardiovascular Medicine & Sciences, The King's British Heart Foundation Centre of Research Excellence, The Rayne Institute, St Thomas' Hospital, London, SE1 7EH, UK.
Tony NgKing's College London, School of Cancer and Pharmaceutical Sciences, Guy's Campus, London, SE1 1UL, UK.
Joseph Robert BurgoyneKing's College London, School of Cardiovascular Medicine & Sciences, The King's British Heart Foundation Centre of Research Excellence, The Rayne Institute, St Thomas' Hospital, London, SE1 7EH, UK.
Philip EatonWilliam Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London, EC1M6BQ, UK. Electronic address: p.eaton@qmul.ac.uk.
William Harvey Research Institute · GBQueen Mary University of London · GBSt Thomas' Hospital · GBKing's College London · GB

Funding

British Heart Foundation FS/14/1/30551British Heart Foundation FS/14/57/31138British Heart Foundation PG/17/44/33064British Heart Foundation PG/19/33/34385Medical Research Council MR/R01065X/1
6 · The paper itself

Abstract

Nitro-oleate (10-nitro-octadec-9-enoic acid), which inhibits soluble epoxide hydrolase (sEH) by covalently adducting to C521, increases the abundance of epoxyeicosatrienoic acids (EETs) that can be health promoting, for example by lowering blood pressure or their anti-inflammatory actions. However, perhaps consistent with their impact on angiogenesis, increases in EETs may exacerbate progression of some cancers. To assess this, Lewis lung carcinoma (LLc1) cells were exposed to oleate or nitro-oleate, with the latter inhibiting the hydrolase and increasing their proliferation and migration in vitro. The enhanced proliferation induced by nitro-oleate was EET-dependent, being attenuated by the ETT-receptor antagonist 14,15-EE-5(Z)-E. LLc1 cells were engineered to stably overexpress wild-type or C521S sEH, with the latter exhibiting resistance to nitro-oleate-dependent hydrolase inhibition and the associated stimulation of tumor growth in vitro or in vivo. Nitro-oleate also increased migration in endothelial cells isolated from wild-type (WT) mice, but not those from C521S sEH knock-in (KI) transgenic mice genetically modified to render the hydrolase electrophile-resistant. These observations were consistent with nitro-oleate promoting cancer progression, and so the impact of this electrophile was examined in vivo again, but this time comparing growth of LLc1 cells expressing constitutive levels of wild-type hydrolase when implanted into WT or KI mice. Nitro-oleate inhibited tumor sEH (P < 0.05), with a trend for elevated plasma 11(12)-EET/DHET and 8(9)EET/DHET (dihydroxyeicosatrienoic acid) ratios when administered to WT, but not KI, mice. Although in vitro studies with LLc1 cells supported a role for nitro-oleate in cancer cell proliferation, it failed to significantly stimulate tumor growth in WT mice implanted with the same LLc1 cells in vivo, perhaps due to its well-established anti-inflammatory actions. Indeed, pro-inflammatory cytokines were significantly down-regulated in nitro-oleate treated WT mice, potentially countering any impact of the concomitant inhibition of sEH.

Indexed as

Epoxide HydrolasesNeoplasmsAlkenesAnimalsEndothelial CellsInflammationMiceAlkenesEpoxide Hydrolases

Identifiers

PMID31926628
PMCPMC6928308
OpenAlexW2995662335

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.